Similarly, the phase 3 IDHENTIFY study enrolling IDH2-mutant R/R AML patients (after the failure of two or three lines of therapy) reported no survival benefit with enasidenib compared with standard of care [67]. This evidence concerns the gene IDH2 and acute myeloid leukemia.